Skip to content

Volumetric Integral Phase-shift Spectroscopy for Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology

VITAL: Volumetric Integral Phase-shift Spectroscopy (VIPS) for the Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03148340
Acronym
VITAL
Enrollment
287
Registered
2017-05-11
Start date
2017-04-14
Completion date
2018-07-15
Last updated
2018-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Hemorrhage, Cerebral Infarction, Cerebral Stroke, Clot (Blood); Brain, Hemorrhage, Intracerebral Hemorrhage, Intracerebral Injury, Ischemic Stroke, Stroke, Stroke, Acute, Subarachnoid Hemorrhage

Brief summary

The purpose of this study is to assess the ability of the Fluids Monitor to detect hemispheric bioimpedance asymmetry associated with acute brain pathology in patients presenting with suspected Acute Ischemic Stroke (AIS).

Detailed description

A prospective non-significant-risk (NSR) multi-site observational study. This study will examine up to 318 subjects undergoing evaluation for acute brain pathology who directly arrive at, or are transferred to, the participating sites.

Interventions

DIAGNOSTIC_TESTVIPS Monitoring

Bioimpedance asymmetry

Sponsors

Cerebrotech Medical Systems, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Must be at least 18 years of age. 2. Being evaluated for acute ischemic stroke. 3. Able to safely wear the study device for up to 2 minutes per reading. 4. Have NIHSS performed before before study device monitoring. 5. Must be able to provide written Informed Consent (either self or via an LAR) at any point during the hospital stay, or if unable to provide such consent, must have permission granted by the governing IRB to enroll in the study (i.e., waiver of consent).

Exclusion criteria

1. Known or suspected traumatic brain injury, either closed or penetrating. 2. Contraindication to neuroimaging, such as a contrast allergy, or other condition that prohibits CT, MRI, and/or angiography. 3. Presence of any implanted electro-stimulating devices in the head and neck. 4. Presence of any large metallic craniofacial implants, such as bone fixation plates, mesh, et cetera. (Note that small metallic objects, such an aneurysm coils, are acceptable.) 5. Presence of an intracranial pressure monitor or any other similar sensor that may compromise the placement of the investigational device. 6. Under arrest or otherwise in custody. 7. Inability to wear the investigational device (skin lesions on scalp, previous intracranial surgeries, etc.). 8. Pregnant or nursing. 9. Any other condition, which in the judgment of the PI would prevent the patient from completing the study or tolerating monitoring sessions and brain imaging, such as mental illness, severe agitation, or hemodynamic instability.

Design outcomes

Primary

MeasureTime frameDescription
Hemispheric bioimpedance asymmetry detectionAt the time of VIPS monitoring - day 0The primary outcome will be the device's ability to detect hemispheric bioimpedance asymmetry associated with acute brain pathology in a population of patients presenting with symptoms consistent with AIS

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026